We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases Draft Guidance on Demonstrating Biosimilarity
FDA Releases Draft Guidance on Demonstrating Biosimilarity
Manufacturers of biosimilars should take great care in designing clinical trials and other steps needed to demonstrate exactly how their products line up with the reference drugs, according to key FDA draft guidance on creating versions of the complex therapies.